Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male brea...

Full description

Saved in:

Bibliographic Details
Published in:	Breast (Edinburgh) 2022-12, Vol.66, p.85-88
Main Authors:	Yıldırım, Hasan Çağrı, Mutlu, Emel, Chalabiyev, Elvin, Özen, Miraç, Keskinkılıç, Merve, Ön, Sercan, Çelebi, Abdussamet, Dursun, Bengü, Acar, Ömer, Kahraman, Seda, Aykan, Musa Barış, Kaman, Ömür, Doğan, Akif, Erdoğan, Atike Pınar, Melisa Celayir, Özde, Günenç, Damla, Güven, Deniz Can, Vedat Bayoğlu, İbrahim, Yavuzşen, Tuğba, Hacıbekiroğlu, İlhan, İnanç, Mevlüde, Kılıçkap, Saadettin, Yalçın, Şuayib, Aksoy, Sercan
Format:	Article
Language:	English
Subjects:	Aminopyridines - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - pathology Breast Neoplasms, Male - drug therapy Cyclin-Dependent Kinase 4 Cyclin-dependent kinase 4–6 inhibitors Cyclin-Dependent Kinase 6 Female Hematology, Oncology, and Palliative Medicine Humans Male Male breast cancer Middle Aged Oncology Original Palbociclib Protein Kinase Inhibitors - therapeutic use Receptor, ErbB-2 - metabolism Ribociclib
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!